Skip to main content
. 2020 Jul 7;10:1000. doi: 10.3389/fonc.2020.01000

Table 1.

ch14.18, ch14.18CHO, and Investigational anti-GD2 mAbs*.

Antibody Description Features
Approved
ch14.18 (dinutuximab) Chimeric (murine-human) IgG1 mAb produced in murine myeloma SP2/0 cell line FDA- and EMA-approved for neuroblastoma
ch14.18/CHO (dinutuximab beta) Chimeric (murine-human) IgG1 mAb produced in CHO cells EMA-approved for neuroblastoma
Investigational
14.18 Murine IgG1 mAb Lower ADCC than 14.G2a
14.G2a Murine IgG2a mAb Used to generate ch14.18
3F8 Murine IgG3 mAb Large experience as single agent and in combinations
Hu3F8 Humanized 3F8 mAb Less complement activation than 3F8
131I-3F8 Murine mAb fused with iodine 131 Radioimmunoconjugate with radioimaging and radioimmunotherapeutic properties
Hu14.18-IL-2 Humanized 14.18 mAb fused with IL-2 Clinical trials of fusion version with IL-2
Hu14.18K322A Point mutation in hu14.18 (biologically modified from 14.G2a) Designed to reduce complement activation and subsequent painful side effects
ME36.1 Murine mAb class switched to IgG1 and IgG2a Cross reacts with GD3
8B6 mAb that binds to O-acetyl-GD2 antigen May reduce painful side effects
L72 Fully human IgM mAb Produced by EBV-transformed cell lines

ADCC, antibody-dependent cellular cytotoxicity; CHO, Chinese hamster ovary; EBV, Epstein-Barr virus; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; mAb, monoclonal antibody.

*

Adapted from Keyel (75).

Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilized by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2).